Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Financial Performance Overview: Rafael Holdings, Inc. reported a net loss of $34.4 million for the fiscal year ending July 31, 2024, significantly higher than the previous year's loss of $8.4 million, primarily due to substantial research and development expenses related to acquisitions.
Merger and Clinical Developments: The company announced a merger agreement with Cyclo Therapeutics, which is conducting a pivotal Phase 3 study for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C1, with interim results expected in mid-2025.
Trade with 70% Backtested Accuracy
Analyst Views on RFL
About RFL
About the author
Rafael Holdings Reports $9.8M Net Loss in Q1, R&D Expenses Rise to $7.5M
- Financial Performance: As of October 31, 2025, Rafael Holdings reported a net loss of $9.8 million for Q1, translating to a loss of $0.19 per share, which is an increase from last year's $9.0 million and $0.37 per share, reflecting the impact of consolidating Cyclo Therapeutics' expenses post-acquisition.
- Surge in R&D Expenses: Research and development expenses soared to $7.5 million this quarter, compared to $1.3 million in the same period last year, primarily due to the inclusion of Cyclo's costs, indicating the company's ongoing commitment to drug development.
- Cash Flow Status: As of October 31, 2025, the company had cash and cash equivalents of $45.5 million, down from $52.8 million on July 31, 2025, highlighting liquidity pressures amid ongoing losses.
- Clinical Trial Progress: Rafael Holdings' Trappsol®Cyclo™ received a recommendation to continue from the Data Monitoring Committee in its pivotal Phase 3 trial for Niemann-Pick Disease Type C1, suggesting the drug could become a significant new treatment option for this rare and fatal genetic disorder.
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Continuation of Phase 3 Study: Rafael Holdings' subsidiary, Cyclo Therapeutics, will continue its pivotal phase 3 TransportNPC study for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1 (NPC1) after a positive interim analysis by an independent Data Monitoring Committee (DMC).
Trappsol® Cyclo™ Overview: Trappsol® Cyclo™, administered intravenously, aims to address the root cause of NPC1 by mobilizing cholesterol from cells, and has shown a favorable safety profile consistent with earlier studies.
Thursday Sector Leaders: Precious Metals, Real Estate Stocks
Real Estate Sector Performance: Real estate shares have shown relative strength, increasing by approximately 1% overall, with Rafael Holdings rising by about 10.7% and Jones Lang LaSalle up by around 2.3% on Thursday.
Market Commentary Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rights Offering Results: Rafael Holdings, Inc. successfully closed a $25 million rights offering, resulting in subscriptions for 3,130,480 shares of Class B common stock, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates will purchase unsubscribed shares through a backstop private placement totaling about $21 million.
Use of Proceeds: The funds raised from the rights offering and backstop private placement are intended to support regulatory approval efforts and potential launch of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, pending positive results from ongoing clinical trials.
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
Rights Offering Announcement: Rafael Holdings, Inc. has announced a rights offering for holders of Class A and B Common Stock, allowing them to purchase shares at a subscription price of $1.28 each, with the subscription period running from May 13 to May 29, 2025.
Eligibility and Participation Details: To participate, holders must be recorded as of May 9, 2025, and former Cyclo Therapeutics shareholders need to exchange their shares for Class B common stock before this date; Howard Jonas will also purchase any unsubscribed shares under a Standby Purchase Agreement.
Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested
Upcoming Stock Splits: Several companies, including Tasman Resources Ltd., Sol-Gel Technologies, and NewGenIVF Group Ltd., are set to undergo reverse stock splits from May 5 to May 9 to maintain compliance with Nasdaq's listing requirements or improve share liquidity.
Company Details: The article highlights specific details of each company's stock split, including the ratio of the split and the effective date, emphasizing their focus areas such as biotechnology, dermatology, and reproductive services.
Rafael Holdings Reports $9.8M Net Loss in Q1, R&D Expenses Rise to $7.5M
- Financial Performance: As of October 31, 2025, Rafael Holdings reported a net loss of $9.8 million for Q1, translating to a loss of $0.19 per share, which is an increase from last year's $9.0 million and $0.37 per share, reflecting the impact of consolidating Cyclo Therapeutics' expenses post-acquisition.
- Surge in R&D Expenses: Research and development expenses soared to $7.5 million this quarter, compared to $1.3 million in the same period last year, primarily due to the inclusion of Cyclo's costs, indicating the company's ongoing commitment to drug development.
- Cash Flow Status: As of October 31, 2025, the company had cash and cash equivalents of $45.5 million, down from $52.8 million on July 31, 2025, highlighting liquidity pressures amid ongoing losses.
- Clinical Trial Progress: Rafael Holdings' Trappsol®Cyclo™ received a recommendation to continue from the Data Monitoring Committee in its pivotal Phase 3 trial for Niemann-Pick Disease Type C1, suggesting the drug could become a significant new treatment option for this rare and fatal genetic disorder.
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Continuation of Phase 3 Study: Rafael Holdings' subsidiary, Cyclo Therapeutics, will continue its pivotal phase 3 TransportNPC study for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1 (NPC1) after a positive interim analysis by an independent Data Monitoring Committee (DMC).
Trappsol® Cyclo™ Overview: Trappsol® Cyclo™, administered intravenously, aims to address the root cause of NPC1 by mobilizing cholesterol from cells, and has shown a favorable safety profile consistent with earlier studies.
Thursday Sector Leaders: Precious Metals, Real Estate Stocks
Real Estate Sector Performance: Real estate shares have shown relative strength, increasing by approximately 1% overall, with Rafael Holdings rising by about 10.7% and Jones Lang LaSalle up by around 2.3% on Thursday.
Market Commentary Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rights Offering Results: Rafael Holdings, Inc. successfully closed a $25 million rights offering, resulting in subscriptions for 3,130,480 shares of Class B common stock, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates will purchase unsubscribed shares through a backstop private placement totaling about $21 million.
Use of Proceeds: The funds raised from the rights offering and backstop private placement are intended to support regulatory approval efforts and potential launch of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, pending positive results from ongoing clinical trials.
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
Rights Offering Announcement: Rafael Holdings, Inc. has announced a rights offering for holders of Class A and B Common Stock, allowing them to purchase shares at a subscription price of $1.28 each, with the subscription period running from May 13 to May 29, 2025.
Eligibility and Participation Details: To participate, holders must be recorded as of May 9, 2025, and former Cyclo Therapeutics shareholders need to exchange their shares for Class B common stock before this date; Howard Jonas will also purchase any unsubscribed shares under a Standby Purchase Agreement.
Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested
Upcoming Stock Splits: Several companies, including Tasman Resources Ltd., Sol-Gel Technologies, and NewGenIVF Group Ltd., are set to undergo reverse stock splits from May 5 to May 9 to maintain compliance with Nasdaq's listing requirements or improve share liquidity.
Company Details: The article highlights specific details of each company's stock split, including the ratio of the split and the effective date, emphasizing their focus areas such as biotechnology, dermatology, and reproductive services.
